miR-155 transgenic mice developed polyclonal lymphoid proliferation followed by acute lymphocytic lymphoma or leukaemia (Costinean et al, 2006).
CTLA-4-deficient mice develop lymphoproliferative disorders characterized by polyclonal T-cell proliferation and early lethality [ 15].
This hypothesis was later confirmed by Costinean et al (2006) who reported an miR-155 transgenic mouse developing a polyclonal pre-leukaemic pre-B-cell proliferation evident in the spleen and bone marrow (BM) followed by a full-blown malignancy.
We developed polyclonal antibodies using an Mbnl3 C-terminal peptide as previously described (Poulos et al., 2013) to characterize Mbnl3 expression in our 129sv mouse ΔE2 moustrainain.
The mice developed F.F.I.
All mice developed interstitial pneumonia and bronchiolitis.
All mice developed atherosclerosis with age.
None of the WT mice developed bacteremia.
All but one unimmunized mouse developed tumours.
The His-tagged FtsZ and Ga5DH were individually used to immunize mice to produce polyclonal antibodies.
